Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
### Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis and reduction of associated heartburn
* Maintenance of healing of erosive esophagitis
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome
### Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing of erosive esophagitis:** 40 mg orally once daily. May consider 20 mg orally once daily.
* **GERD (symptomatic relief):** 20 mg orally once daily for up to 4 weeks.
* **Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome):** Initiate at 40 mg orally or intravenously twice daily. Doses may be adjusted upwards based on clinical response. Doses up to 240 mg IV daily have been administered.
### Pediatric Dosing
* **Healing of erosive esophagitis (ages 5 to 16 years):** 20 mg or 40 mg orally once daily for up to 8 weeks. The appropriate dose depends on the severity of esophagitis.
* **GERD (ages 5 to 16 years):** 20 mg orally once daily for up to 4 weeks.
### Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 40 mg orally once daily.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* Long-term use may be associated with an increased risk of *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
### Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** May decrease absorption of drugs such as ketoconazole, itraconazole, posaconazole, erlotinib, and nelfinavir.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution with drugs primarily metabolized by this enzyme (e.g., clopidogrel, voriconazole).
### Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, tetany, seizures, arrhythmias).
* Monitor for signs of *Clostridioides difficile* infection.
* Consider monitoring vitamin B12 levels with long-term therapy.
* Monitor bone mineral density in patients at risk for osteoporosis.
### Clinical Pearls
* Administer oral pantoprazole at least 30 minutes before a meal.
* IV administration: Reconstitute and further dilute as per manufacturer instructions. Infuse over 15 minutes.
* Do not crush or chew delayed-release tablets.
* For patients unable to swallow intact tablets, oral suspension can be prepared by emptying intact tablets into a clean container and mixing with 10 mL of water or applesauce; consume immediately.
***
*Disclaimer: This information is intended for clinical use and does not replace comprehensive drug information resources. Always verify current prescribing information and consult appropriate resources before making clinical decisions.*
